US ClinicalTrials.gov Biotech, Pharma Sponsor & Recruiting Study Radar

Extract structured clinical trial pipelines, biotech/pharma sponsors, drug interventions, enrollment metrics, central contacts, and hospital site counts directly from the official U.S. National Library of Medicine / NIH ClinicalTrials.gov REST API v2 (https://clinicaltrials.gov/api/v2/studies).

Designed for Contract Research Organizations (CROs), Biotech Venture Capital & Private Equity analysts, Pharma Business Development teams, Clinical Recruitment agencies, and AI Healthcare Research Agents (MCP-ready).

---

Key Features

• Official NIH ClinicalTrials.gov v2 Integration: Real-time access to registered clinical studies without fragile HTML scraping.
• Biotech & Pharma Sponsor Profiling: Identifies leadSponsorName, leadSponsorClass (INDUSTRY, NIH, FED, OTHER), and collaborating institutions.
• Pipeline & Intervention Intelligence: Extracts trial phases (PHASE1, PHASE2, PHASE3, PHASE4), enrollmentCount, target conditions, and drug/device/biological interventions.
• Site & Central Contact Extraction: Captures centralContacts (names, roles, phone numbers, emails) and total participating clinical locations (locationsCount + site sample).
• LLM-Ready Markdown Trial Brief: Automatically generates a clean, structured markdownTrialBrief per study for RAG pipelines, AI agents, and automated CRM enrichment.
• MCP Server Enabled: Native Model Context Protocol (mcpServer: true) compatibility for Claude, Cursor, and autonomous research workflows.

---

Input Parameters

Field	Type	Default	Description
condition	string	"Diabetes"	Disease, medical condition, or therapeutic area query (e.g., "Diabetes", "Oncology", "Obesity").
overallStatus	string	"RECRUITING"	Recruitment status filter: RECRUITING, NOT_YET_RECRUITING, ACTIVE_NOT_RECRUITING, COMPLETED, or ALL.
maxResults	integer	10	Maximum number of studies to return (1 to 100).

---

Output Dataset Example

{
  "nctId": "NCT06123456",
  "briefTitle": "Phase 2 Study of GLP-1/GIP Dual Agonist in Type 2 Diabetes Mellitus",
  "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial Evaluating Efficacy and Safety in Adults With Type 2 Diabetes",
  "overallStatus": "RECRUITING",
  "leadSponsorName": "Apex Biotech Therapeutics Inc.",
  "leadSponsorClass": "INDUSTRY",
  "phases": ["PHASE2"],
  "enrollmentCount": 240,
  "conditions": ["Type 2 Diabetes Mellitus", "Metabolic Syndrome"],
  "interventions": [
    {
      "type": "DRUG",
      "name": "ABT-890 Dual Agonist",
      "description": "Subcutaneous weekly injection"
    }
  ],
  "centralContacts": [
    {
      "name": "Clinical Trials Operations Desk",
      "role": "CONTACT",
      "phone": "+1-800-555-0199",
      "email": "trials@apexbiotech.example.com"
    }
  ],
  "locationsCount": 18,
  "studyUrl": "https://clinicaltrials.gov/study/NCT06123456",
  "markdownTrialBrief": "## [NCT06123456] Phase 2 Study of GLP-1/GIP Dual Agonist in Type 2 Diabetes Mellitus\n..."
}